Immunemodulation: Cancer drug trial halted after three test subjects die
July 12, 2016 – The American Food & Drug Administration (FDA) has notified Juno Therapeutics Inc. that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute …
Immunemodulation: Cancer drug trial halted after three test subjects die Read more »